Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Little Product Overlap, Pfizer/Wyeth Commercial Synergies Are Subtle

Executive Summary

Commercial synergies clearly are not driving Pfizer's pending acquisition of Wyeth. The companies have said that their marketed products are largely complementary with little overlap, and analysts agree

You may also be interested in...

Niche, Lackluster: Two Words That Sum Up 2008 NME Launches

The year 2008 won't go down as the bleakest for new molecular entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior

Market Snapshot: Anti-TNFs Grow Despite Tough Market

At least one class of therapies - anti-tumor necrosis factors - is booming, even in the midst of one of the worst years financially for the pharmaceutical industry

Pfizer Restructures For A More Flexible Future

In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care and emerging markets





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts